Sign In
Buy AMRS
$0.0500
+0 (+0%)
At Close: Nov 27, 2023
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Amyris, Inc. (AMRS) on Behalf of Investors
11:00am, Monday, 26'th Oct 2020
BENSALEM, Pa.--(BUSINESS WIRE)---- $AMRS #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Amyris, Inc. (AMRS) on Behalf of Investors
The
Amyris (NASDAQ:AMRS) Stock Price Down 6.9%
04:54am, Sunday, 18'th Oct 2020
Amyris, Inc. (NASDAQ:AMRS) fell 6.9% during trading on Friday . The stock traded as low as $2.82 and last traded at $2.82. 1,523,948 shares traded hands during mid-day trading, a decline of 37% from t
The Law Offices of Frank R. Cruz Announces Investigation of Amyris, Inc. (AMRS) on Behalf of Investors
12:00am, Thursday, 08'th Oct 2020
The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Amyris, Inc (“Amyris” or the “Company”) (NASDAQ:
Why Amyris Fell 11% in September | The Motley Fool
01:22pm, Wednesday, 07'th Oct 2020
It could have been a lot worse.
R&D Surprises Offer Amyris Unbounded Upside (NASDAQ:AMRS)
02:00pm, Wednesday, 30'th Sep 2020
Amyris' engineered yeast strains and advanced fermentation can produce an unlimited number of new products for billion-dollar markets.
Amyris On Track For Cash Flow, Earnings And 70%/Year Returns (NASDAQ:AMRS)
06:38pm, Tuesday, 29'th Sep 2020
Amyris bolsters balance sheet, shifting focus to cash flow, 40-50% revenue growth and earnings (we estimate $0.72 EPS in 2024).
Amyris Inc (NASDAQ:AMRS) Shares Purchased by American International Group Inc.
04:46am, Thursday, 24'th Sep 2020
American International Group Inc. increased its stake in shares of Amyris Inc (NASDAQ:AMRS) by 21.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securi
Amyris Patent Lawsuit, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:AMRS)
02:07pm, Thursday, 17'th Sep 2020
Amyris Inc. suffers a setback over patent lawsuit.
Why Amyris Shares Dropped 26% Today | The Motley Fool
08:22pm, Friday, 11'th Sep 2020
The company has responded to a $881 million lawsuit brought against it yesterday.
Mid-Afternoon Market Update: Nasdaq Drops Over 100 Points; A-Mark Precious Metals Shares Spike Higher
12:00am, Friday, 11'th Sep 2020
Toward the end of trading Friday, the Dow traded up 0.26% to 27607.31 while the NASDAQ fell 1.05% to 10805.00. The S&P also fell, dropping 0.24% to 3331.34.
The U.S. has the...
Oppenheimer: These 3 Penny Stocks Have Triple-Digit Upside Potential
03:12pm, Thursday, 10'th Sep 2020
These penny stocks are company names that won’t break the bank, and boast colossal growth prospects for the 12 months ahead.
Amyris: Avoid The Shares Until Key Cannabinoid Collaboration Issues And Capital Requirements Have Been Addressed
10:32am, Wednesday, 19'th Aug 2020
Discussing key takeaways from the company's Q2/2020 earnings report. Management reiterated aggressive top- and bottom-line projections.
Amyris Appoints Sheila Shekar Pollak As Chief Marketing Officer Of Biossance
12:30pm, Friday, 14'th Aug 2020
Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands and a top supplier of sustainable and natural ingredients, today a
Amyris Reports Its Largest First-Half Operating Loss Since 2012 | The Motley Fool
04:45pm, Friday, 07'th Aug 2020
A growing balance of deferred cost of product revenue suggests business fundamentals might be significantly worse than reported.
